BioAdaptives appoints Dr. Yaguang Liu to board and increases authorized shares to 1.25 billion

BIOADAPTIVES, INC.

Dr. Yaguang Liu appointed to board effective April 5, 2023; holds 32 US patents on natural botanicals.
Authorized common stock increased from 750M to 1.25B shares; preferred shares authorized at 10M.
Amendment approved by board and majority shareholders on March 6, 2023, effective March 27, 2023.
Dr. Liu is founder of L.Y. Research Corp and has experience with FDA IND applications and clinical studies.

item 5.02 item 5.03 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Dr. Yaguang Liu

Board of Directors

BDPT · BIOADAPTIVES, INC.

Effective: 2023-04-05
Filed: April 6, 2023, 7:59 PM ET

On April 5, 2023, the Company appointed Dr. Yaguang Liu to its Board of Directors.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Yaguang Liu was appointed as Board of Directors at BIOADAPTIVES, INC..

Action: appointed
Role: Board of Directors

Exact text from the filing

On April 5, 2023, the Company appointed Dr. Yaguang Liu to its Board of Directors.

View on SEC.gov

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.95

BIOADAPTIVES, INC.: Amended Articles of Incorporation to increase authorized shares of common stock from 750,000,000 to 1,250,000,000 shares and authorize 10,000,000 preferred shares (effective 2023-03-27).

Change: charter amendment
Effective: 2023-03-27

Exact text from the filing

On March 6, 2023, the Company’s board and a majority of its shareholders approved an amendment to the Company’s Articles of Incorporation to increase the authorized number of shares of its common stock, par value .0001, from 750,000,000 shares to 1,250,000,000 shares of which 10,000,000 may be preferred shares. The increase became effective March 27, 2023.

View on SEC.gov

Browse all governance changes →

BIOADAPTIVES, INC. filing history →

Source: SEC EDGAR

accession 0001640334-23-000587

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.